UVB Treatment in Paediatric Atopic Dermatitis
Research type
Research Study
Full title
Assessing long term efficacy impact and potential clinical predictors of response to narrowband ultraviolet B in children with atopic eczema
IRAS ID
201165
Contact name
Shiela Clark
Contact email
Sponsor organisation
Leeds Teaching Hospitals NHS Trust
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
This trial is a prospective, single centre, open, observational study of paediatric patients with atopic eczema who are referred for treatment with narrowband UVB as part of their standard treatment conducted in the Department of Dermatology, Chapel Allerton Hospital, Leeds.
This study will investigate a paediatric population (age less than or equal to 16 years old) with moderate or severe atopic eczema that has not responded to topical therapy alone. The planned sample size is 60 children treated with UVB recruited over a 4-year study period. Overall study time will be 15 months per patient. The active intervention arm will be compared with a control arm of patients who qualify for, but decline, UVB treatment.
The main objective is to assess how effective UVB treatment is in this cohort of patients up to 12 months after treatment. We also plan to determine if any specific clinical factors may influence how well is patient is likely to do with UVB, the impact of treatment on patient quality of life, and any adverse outcomes from treatment.
REC name
London - Brent Research Ethics Committee
REC reference
16/LO/1930
Date of REC Opinion
19 Oct 2016
REC opinion
Favourable Opinion